Movement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target

Market Focus06-24

On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.

On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.

Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148915961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 16:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148915961","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target","media":"Market Focus","content":"<p><p>On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.</p><p>On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.</p><p>Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Argenx SE Rises 3.55% in Pre-Market Trading, BNP Paribas Initiates Outperform Rating with $1,219 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-24 16:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.</p><p>On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.</p><p>Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARGX","symbol_name":"Argenx SE","start_time":0,"source_url":"","article_id":"1148915961","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148915961","pubTimestamp":1782288462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARGX":"Argenx SE"},"translate_title":"走势提示|Argenx SE盘前涨3.55%法巴启动跑赢大盘评级目标1219美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARGX":1},"content_text":"On June 24, Argenx SE rose 3.55% in pre-market trading, trading at $868.83/share, with turnover of $20,300.On the news front, BNP Paribas recently initiated coverage on Argenx with an Outperform rating and set a target price of $1,219, implying approximately 40% upside from the current stock price. According to FactSet data, the stock carries an average analyst rating of Buy with a mean target price of $1,064.53. BNP Paribas's target price stands notably above market consensus, providing a positive catalyst for sentiment and extending the stock's recent upward momentum.Argenx SE is a commercial-stage global biopharmaceutical company focused on developing differentiated therapies for severe autoimmune diseases. Its lead product candidate, efgartigimod, targets conditions including myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company maintains strategic partnerships with AbbVie, Zai Lab, and LEO Pharma, among others.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148915961","isCrawlerRequest":true}